ZyVersa Therapeutics, Inc.
Price Action
Technical Summary
CONSOLIDATINGZyVersa Therapeutics, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is weak (RS Rating: 31), showing significant lag compared to the market leaders. Earnings growth of 70% provides fundamental context to the price action. Investors should exercise caution due to high volatility (159% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.18 | -9.39% | BELOW |
| 50 SMA | $0.19 | -16.00% | BELOW |
| 100 SMA | $0.21 | -22.81% | BELOW |
| 150 SMA | $0.19 | -15.65% | BELOW |
| 200 SMA | $0.18 | -11.10% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ZVSA in an uptrend right now?
ZVSA has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is ZVSA overbought or oversold?
ZVSA's RSI (14) is 43. The stock is in neutral territory, neither overbought nor oversold.
Is ZVSA outperforming the market?
ZVSA has a Relative Strength (RS) Rating of 31 out of 99. ZVSA is currently lagging the broader market.
Where is ZVSA in its 52-week range?
ZVSA is trading at $0.16, which is 10% of its 52-week high ($1.67) and 3% above its 52-week low ($0.11).
How volatile is ZVSA?
ZVSA has a Beta of 0.31 and 52-week volatility of 159%. It's less volatile than the S&P 500 - generally more stable.